Hangzhou Edcheng Pharmaceutical Technology

Hangzhou Edcheng Pharmaceutical Technology is a China-based biotechnology company focused on the discovery and development of innovative small molecule therapeutics. The company specializes in medicinal chemistry and the optimization of lead compounds, with a primary focus on the Janus kinase (JAK) family of enzymes. Edcheng's research efforts are directed toward creating high-potency, selective inhibitors for the treatment of autoimmune and inflammatory conditions such as rheumatoid arthritis and psoriasis. By leveraging advanced chemical synthesis techniques, including deuteration technology, the company aims to develop drug candidates with improved metabolic stability and superior safety profiles compared to existing therapies.